Focus on rare diseases projects
Commercially-viable model
Potential to translate into clinics within 2-4 years
Technology-agnostic
we
projects
and we
founders
to
champions
how we help founders
• Business development
• Competitive analysis
• Market studies
• Business plan and budget
• Accounting and tax credit
• Fundraising
• Headhunt of key profiles
• Program « Coach the founders »
• HR regular consulting
• Name and branding strategy
• Visual identity
• Website
• POC consolidation
• Non-clinical development
• CMC
• Regulatory & Clinical strategy
• Startup incorporation and administration
• Contract management
• IP protection and strategy
how we help founders
STRATEGY
FINANCE
HUMAN RESSOURCES
MARKETING
R&D
LEGAL & IP
AMPLEIA INVESTMENT SELECTION PROCESS
hundreds
diseases monitored
Create the widest and most diversified portfolio of promising projects for rare diseases
30-50
mature projects followed-up
• Research-grade PoC in vitro, in cellular models and in vivo.
• Preliminary non-toxicity elements are a plus.
• Product optimization on-going or completed (incl. Construct/design, formulation, RoA…)
• IP-protected construct
Potential for economically-viable commercialization
• Eligible patient pool i.e. incidence, prevalence, est. inclusion criteria, competition
• Technology modality and pricing background
• Curative potential
Assessments of incubation and exit options for Ampleia
• Budget and resources allocation assessment
• Single-asset program vs. Ubiquitous technology-platform
• Appetite assessment from pharma for strategic partnering and VCs for syndication
• Timing for exit (i.e. end of incubation)
20
We will perform due-diligence across the following expertise:
Intellectual Property Preclinical development plan
Scientific & Medical needs Human Resources
investment committee
Presentation to the investment committee composed of experts and executives from biopharma industry, therapeutic development and VCs
4 NEW
projects
EACH YEAR
hundreds
diseases monitored
Create the widest and most diversified portfolio of promising projects for rare diseases
30-50
mature projects followed-up
• Research-grade PoC in vitro, in cellular models and in vivo.
• Preliminary non-toxicity elements are a plus.
• Product optimization on-going or completed (incl. Construct/design, formulation, RoA…)
• IP-protected construct
Potential for economically-viable commercialization
• Eligible patient pool i.e. incidence, prevalence, est. inclusion criteria, competition
• Technology modality and pricing background
• Curative potential
Assessments of incubation and exit options for Ampleia
• Budget and resources allocation assessment
• Single-asset program vs. Ubiquitous technology-platform
• Appetite assessment from pharma for strategic partnering and VCs for syndication
• Timing for exit (i.e. end of incubation)
20
We will perform due-diligence across the following expertise:
Intellectual Property Preclinical development plan
Scientific & Medical needs Human Resources
investment committee
Presentation to the investment committee composed of experts and executives from biopharma industry, therapeutic development and VCs
4 NEW
projects
EACH YEAR
hundreds
diseases monitored
Create the widest and most diversified portfolio of promising projects for rare diseases
30-50
mature projects followed-up
• Research-grade PoC in vitro, in cellular models and in vivo.
• Preliminary non-toxicity elements are a plus.
• Product optimization on-going or completed (incl. Construct/design, formulation, RoA…)
• IP-protected construct
Potential for economically-viable commercialization
• Eligible patient pool i.e. incidence, prevalence, est. inclusion criteria, competition
• Technology modality and pricing background
• Curative potential
Assessments of incubation and exit options for Ampleia
• Budget and resources allocation assessment
• Single-asset program vs. Ubiquitous technology-platform
• Appetite assessment from pharma for strategic partnering and VCs for syndication
• Timing for exit (i.e. end of incubation)
20
We will perform due-diligence across the following expertise:
Intellectual Property Preclinical development plan
Scientific & Medical needs Human Resources
investment committee
Presentation to the investment committee composed of experts and executives from biopharma industry, therapeutic development and VCs
4 NEW
projects
EACH YEAR
